SARS-CoV-2 infection rates after different vaccination schemes: An online survey in Turkey

Oya Baydar TOPRAK; Sennur OZEN; Berker OZTURK; Burcu OZTURK; Nurdan KOKTURK; Ebru OZTURK; Mehmet KITAPCI

Return

SARS-CoV-2 infection rates after different vaccination schemes: An online survey in Turkey

Author: Oya Baydar TOPRAK ¹ ; Sennur OZEN ² ; Berker OZTURK ³ ; Burcu OZTURK ⁴ ; Nurdan KOKTURK ⁴ ; Ebru OZTURK ⁵ ; Mehmet KITAPCI ⁶
Author Information

1. Chest Diseases Department, Faculty of Medicine, Cukurova University
2. Department of Pulmonary Medicine, Delta Hospital
3. Chest Diseases Department, Aksaray Training and Research Hospital
4. Department of Pulmonary Medicine, Faculty of Medicine, Gazi University
5. Department of Biostatistics, Hacettepe University
6. Department of Nuclear Medicine, Integra Medical Imaging Center
Publication Type:Journal Article
Keywords: COVID-19; mRNA vaccine; Positivity rate after vaccination; Reinfection; SARS-CoV-2; Vaccine schemes
From: Asian Pacific Journal of Tropical Medicine 2022;15(4):171-178
CountryChina
Language:Chinese
Abstract: Objective: To identify effects of various nationwide vaccination protocols on the evolution of new SARS-CoV-2 infections among adult population and to evaluate the safety of mRNA (BioNTech/ Pfizer) vaccine. Methods: Totally 10 735 adult volunteers that received at least one dose of BioNTech/Pfizer or triple doses of CoronaVac participated in this cross-sectional-online survey between 1 and 10 September 2021. The information was collected covering a 5-month period from April 2021 to September 2021. Information about people who were vaccinated with only single and double dose CoronaVac were not included in this study. Results: At least one side effect after single and double dose of BioNTech/Pfizer and triple doses of CoronaVac were observed in 42.1%, 42.5% and 10.9%, respectively. The most common side effects were shoulder/arm pain, weakness/fatigue, muscle/joint pain and headache. The side effects were the most frequent in single BioNTech/Pfizer, while it was the least in triple CoronaVac. The rate of positive PCR tests before vaccination was 17.6%, and decreased to 3.0% after vaccination. The rates of positive SARS CoV-2-PCR were 18.8%, 3.5%, 3.1%, 0.5% and 4.6% in single BioNTech/Pfizer, double BioNTech/Pfizer, double CoronaVac+single BioNTech/Pfizer, double CoronaVac+double BioNTech/Pfizer and triple CoronaVac, respectively. While 1.8% of PCR positive COVID-19 cases needed intensive unit care in the pre-vaccination period, intensive care unit was required in 0%, 1.5%, 2.4%, 0% and 4.2% after single BioNTech/ Pfizer, double BioNTech/Pfizer, double CoronaVac+single BioNTech/ Pfizer, double CoronaVac+double BioNTech/Pfizer and triple CoronaVac, respectively. Reinfection rate after vaccination was 0.4%. Conclusions: The rarity of COVID-19 infection after vaccination suggests that efficacy of vaccines is maintained. On the other hand, the data underscore the critical importance of continued public health mitigation.